Ibio Inc (IBIO)

$1.61 -0.05 (-3.01%)
Market Cap 60.00M
Revenue (ttm) 400,000.00
Net Income (ttm) -18.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,595.00%
Debt to Equity Ratio 0.01
Volume 396,800
Avg Vol 992,612
Day's Range N/A - N/A
Shares Out 36.14M
Stochastic %K 33%
Beta 1.23
Analysts Strong Sell
Price Target $5.46

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology
Sector: Healthcare
Phone: 979 446 0027
Website: ibioinc.com
Address:
11750 Sorrento Valley Road, Suite 200, San Diego, United States
focafoca99
focafoca99 May. 12 at 8:27 PM
$IBIO released its quarter ended March 31, 2026 financial results via a press release. https://www.rapidticker.com/news/ibio-sec-filing-bb0785
0 · Reply
Joelew22
Joelew22 May. 12 at 5:54 PM
$IBIO Ibios linkedin page recently highlights Dr. Stoner and her role at MPM BioImpact. Maybe this will give Brenner insight into shareholders perspectives in combination with the science behind ibios efforts.
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter May. 12 at 4:57 PM
$IBIO
1 · Reply
BIOCOIN
BIOCOIN May. 12 at 2:30 PM
$IBIO 20 may important!!!?
0 · Reply
KindnessWins
KindnessWins May. 11 at 6:12 PM
$IBIO this thing wants to rip our faces off
1 · Reply
FASTV12
FASTV12 May. 9 at 10:44 PM
$IBIO
0 · Reply
WZMAN7227
WZMAN7227 May. 9 at 12:29 PM
$IBIO https://www.linkedin.com/posts/jonchee_biotechnology-lifesciences-podcast-share-7458218759103692800-vrBN?utm_source=share&utm_medium=member_ios&rcm=ACoAABcnGdIBccvXqAqSYm1rjD19vQBtthG68oU
1 · Reply
focafoca99
focafoca99 May. 8 at 8:34 PM
$IBIO elevated Dr. Elizabeth Stoner to its board as a Class II director. https://www.rapidticker.com/news/ibio-sec-filing-1baf2a
0 · Reply
Joelew22
Joelew22 May. 8 at 7:53 PM
$IBIO new board member seems to be a good fit for ibios strategy.
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter May. 8 at 5:54 PM
$IBIO BIG BOYS KNOW! LOADING ZONE!
1 · Reply
Latest News on IBIO
iBio reports Q3 EPS (7c), consensus (6c)

2026-05-12T21:36:01.000Z - 15 hours ago

iBio reports Q3 EPS (7c), consensus (6c)

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

May 12, 2026, 4:05 PM EDT - 17 hours ago

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. Transcript: Status update

Apr 8, 2026, 2:00 PM EDT - 4 weeks ago

iBio, Inc. Transcript: Status update

iBio receives regulatory clearance to initiate IBIO-600 trial in Australia

2026-04-08T11:12:57.000Z - 5 weeks ago

iBio receives regulatory clearance to initiate IBIO-600 trial in Australia

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

Apr 8, 2026, 7:00 AM EDT - 5 weeks ago

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

Biotech Alert: Searches spiking for these stocks today

2026-03-30T16:21:02.000Z - 6 weeks ago

Biotech Alert: Searches spiking for these stocks today

ACOG

iBio, Inc. Transcript: Study update

Mar 17, 2026, 4:00 PM EDT - 2 months ago

iBio, Inc. Transcript: Study update

iBio to provide update on cardiopulmonary program

2026-03-16T20:40:52.000Z - 2 months ago

iBio to provide update on cardiopulmonary program

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Mar 16, 2026, 4:30 PM EDT - 2 months ago

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio, Inc. Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:20 PM EDT - 2 months ago

iBio, Inc. Transcript: Leerink Global Healthcare Conference 2026

iBio announces new preclinical data from study evaluating IBIO-610

2026-03-09T11:10:09.000Z - 2 months ago

iBio announces new preclinical data from study evaluating IBIO-610

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

Mar 9, 2026, 7:00 AM EDT - 2 months ago

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio initiated with a Buy at JonesResearch

2026-03-02T21:34:02.000Z - 2 months ago

iBio initiated with a Buy at JonesResearch

iBio files $200M mixed securities shelf

2026-02-27T21:36:51.000Z - 2 months ago

iBio files $200M mixed securities shelf

Biotech Alert: Searches spiking for these stocks today

2026-02-27T16:00:56.000Z - 2 months ago

Biotech Alert: Searches spiking for these stocks today

iBio, Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 2:00 PM EST - 2 months ago

iBio, Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

iBio to Participate in Upcoming Investor Conferences

Feb 24, 2026, 7:00 AM EST - 2 months ago

iBio to Participate in Upcoming Investor Conferences

iBio reports Q2 EPS (9c), consensus (6c)

2026-02-10T21:13:10.000Z - 3 months ago

iBio reports Q2 EPS (9c), consensus (6c)

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Feb 10, 2026, 4:05 PM EST - 3 months ago

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio prices 11.06M shares at $2.35 in private placement

2026-01-09T12:13:56.000Z - 4 months ago

iBio prices 11.06M shares at $2.35 in private placement

iBio Announces $26 Million Private Placement

Jan 9, 2026, 7:00 AM EST - 4 months ago

iBio Announces $26 Million Private Placement

Biotech Alert: Searches spiking for these stocks today

2026-01-08T17:16:04.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

iBio initiated with an Outperform at LifeSci Capital

2025-12-18T14:06:19.000Z - 5 months ago

iBio initiated with an Outperform at LifeSci Capital

ARWR WVE

iBio initiated with an Outperform at LifeSci Capital

2025-12-18T13:41:09.000Z - 5 months ago

iBio initiated with an Outperform at LifeSci Capital

Biotech Alert: Searches spiking for these stocks today

2025-12-11T16:45:34.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today

CAMP

Biotech Alert: Searches spiking for these stocks today

2025-12-10T15:25:54.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today

Biotech Alert: Searches spiking for these stocks today

2025-12-09T16:35:29.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today

3 Penny Stocks to Watch Now, 12/9/25

2025-12-09T16:17:00.000Z - 5 months ago

3 Penny Stocks to Watch Now, 12/9/25

RR TSLA WBUY

iBio, Inc. Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 8:45 AM EST - 5 months ago

iBio, Inc. Transcript: Evercore ISI 8th Annual HealthCONx Conference

iBio to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 4:15 PM EST - 6 months ago

iBio to Participate in the 8th Annual Evercore Healthcare Conference

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 6 months ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:30 AM EST - 6 months ago

iBio, Inc. Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 30, 2025, 7:00 AM EDT - 6 months ago

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 23, 2025, 7:00 AM EDT - 7 months ago

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Oct 21, 2025, 7:00 AM EDT - 7 months ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Sep 5, 2025, 7:30 AM EDT - 8 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

iBio Announces Closing of $50 Million Public Offering

Aug 25, 2025, 7:00 AM EDT - 9 months ago

iBio Announces Closing of $50 Million Public Offering

iBio Announces Pricing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 9 months ago

iBio Announces Pricing of $50 Million Public Offering

iBio Announces Proposed Public Offering

Aug 18, 2025, 4:01 PM EDT - 9 months ago

iBio Announces Proposed Public Offering

iBio, Inc. Transcript: Study Update

Jun 24, 2025, 8:30 AM EDT - 11 months ago

iBio, Inc. Transcript: Study Update

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 24, 2025, 7:00 AM EDT - 11 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 23, 2025, 4:15 PM EDT - 11 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Jun 16, 2025, 7:00 AM EDT - 11 months ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025, 8:00 AM EDT - 1 year ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 29, 2025, 1:43 PM EDT - 1 year ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 22, 2025, 8:00 AM EDT - 1 year ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Apr 7, 2025, 7:00 AM EDT - 1 year ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 19, 2025, 4:05 PM EST - 1 year ago

iBio to Begin Trading on the Nasdaq Stock Exchange

iBio Reports Fiscal Second Quarter 2025 Financial Results

Feb 10, 2025, 4:05 PM EST - 1 year ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Jan 2, 2025, 7:00 AM EST - 1 year ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio Reports Fiscal First Quarter 2025 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Aug 12, 2024, 4:30 PM EDT - 1 year ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio Closes Sale of Manufacturing Facility in Texas

Jun 3, 2024, 7:00 AM EDT - 2 years ago

iBio Closes Sale of Manufacturing Facility in Texas

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 4:05 PM EDT - 2 years ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 2:43 PM EDT - 2 years ago

iBio stock nearly tripled on Wednesday: here's why

iBio, Inc. Transcript: Collaboration

Mar 27, 2024, 8:30 AM EDT - 2 years ago

iBio, Inc. Transcript: Collaboration

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 27, 2024, 7:00 AM EDT - 2 years ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

iBio Announces $15.0 Million Private Placement

Mar 26, 2024, 7:35 PM EDT - 2 years ago

iBio Announces $15.0 Million Private Placement

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Feb 26, 2024, 7:45 AM EST - 2 years ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 8:15 AM EST - 2 years ago

iBio Announces Participation in 23rd Annual PepTalk Conference

iBio Amends and Extends Maturity of Credit Agreement

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

iBio Announces Reverse Stock Split

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

iBio Explains Recent Filing of Registration Statement

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

iBio Announces Amendment to Credit Agreement with Woodforest

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Aug 14, 2023, 4:15 PM EDT - 2 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 27, 2023, 8:00 AM EDT - 3 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

iBio Forges Research Collaboration with the National Institutes of Health

Jun 12, 2023, 4:15 PM EDT - 3 years ago

iBio Forges Research Collaboration with the National Institutes of Health

iBio to Participate in the JMP Securities Life Sciences Conference

May 9, 2023, 4:30 PM EDT - 3 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Apr 4, 2023, 4:05 PM EDT - 3 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Mar 31, 2023, 8:10 AM EDT - 3 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

focafoca99
focafoca99 May. 12 at 8:27 PM
$IBIO released its quarter ended March 31, 2026 financial results via a press release. https://www.rapidticker.com/news/ibio-sec-filing-bb0785
0 · Reply
Joelew22
Joelew22 May. 12 at 5:54 PM
$IBIO Ibios linkedin page recently highlights Dr. Stoner and her role at MPM BioImpact. Maybe this will give Brenner insight into shareholders perspectives in combination with the science behind ibios efforts.
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter May. 12 at 4:57 PM
$IBIO
1 · Reply
BIOCOIN
BIOCOIN May. 12 at 2:30 PM
$IBIO 20 may important!!!?
0 · Reply
KindnessWins
KindnessWins May. 11 at 6:12 PM
$IBIO this thing wants to rip our faces off
1 · Reply
FASTV12
FASTV12 May. 9 at 10:44 PM
$IBIO
0 · Reply
WZMAN7227
WZMAN7227 May. 9 at 12:29 PM
$IBIO https://www.linkedin.com/posts/jonchee_biotechnology-lifesciences-podcast-share-7458218759103692800-vrBN?utm_source=share&utm_medium=member_ios&rcm=ACoAABcnGdIBccvXqAqSYm1rjD19vQBtthG68oU
1 · Reply
focafoca99
focafoca99 May. 8 at 8:34 PM
$IBIO elevated Dr. Elizabeth Stoner to its board as a Class II director. https://www.rapidticker.com/news/ibio-sec-filing-1baf2a
0 · Reply
Joelew22
Joelew22 May. 8 at 7:53 PM
$IBIO new board member seems to be a good fit for ibios strategy.
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter May. 8 at 5:54 PM
$IBIO BIG BOYS KNOW! LOADING ZONE!
1 · Reply
suredubb
suredubb May. 8 at 3:49 PM
$IBIO major loading zone… always volatile…. great time to scale in…all about the base
0 · Reply
focafoca99
focafoca99 May. 8 at 11:35 AM
$IBIO named Dr. Elizabeth Stoner to its board of directors. https://www.rapidticker.com/news/ibio-ibio-appoints-distinguished-biotech-leader-990730
1 · Reply
Rower5oh
Rower5oh May. 8 at 11:28 AM
$IBIO
1 · Reply
Stock_Catcher
Stock_Catcher May. 8 at 3:04 AM
Fortune Friday Watchlist Pt. 8 $SABS $INO $SNES $CODX $IBIO Let's Bank Tomorrow
0 · Reply
investimakerrr
investimakerrr May. 7 at 11:32 PM
$WTO $IBIO $JEM $NPT still here
2 · Reply
ElginOnST
ElginOnST May. 7 at 10:11 PM
$IXHL $NVAX $CHSN $AMS $IBIO GREAT summary! 👏 Unreal Bio setup 👀🤯 Easiest hold of my life 💎👐
0 · Reply
ElginOnST
ElginOnST May. 7 at 8:54 PM
$NVAX $XWEL $IBIO $ONCO Don't sleep on this Bio play. Reminds me of $IXHL last year before it ran.
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter May. 6 at 11:22 PM
$IBIO https://investor.lilly.com/news-releases/news-release-details/lilly-commits-additional-45-billion-across-indiana-manufacturing
1 · Reply
FkDisManipulation
FkDisManipulation May. 6 at 9:03 PM
$IBIO Midget fgt i told you 🤡
3 · Reply
LETS_Gooooo
LETS_Gooooo May. 6 at 7:55 PM
$IBIO
0 · Reply
DeVries007
DeVries007 May. 6 at 5:48 PM
$IBIO This one had a history of making big jumps. Something brewing and the chart is giving me that fibe.
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter May. 6 at 5:29 PM
$IBIO SMART MONEY!!!!!!
1 · Reply